

STEP THERAPY POLICY

POLICY: Topical Acne – Cleansers Step Therapy Policy

Note: This is not an inclusive list.

- Avar[™] (sodium sulfacetamide/sulfur 9.5%/5% cleansing pads Mission)
- Avar[™] LS (sodium sulfacetamide/sulfur 10%/2% cleansing pads Mission)
- BP 10-1 Wash (sodium sulfacetamide 10%/sulfur 1% wash Acella, generic)
- BP Cleansing Wash (sulfacetamide 10%/sulfur 4%/urea 10% Acella, generic)
- Pacnex® 7% Topical Wash (benzoyl peroxide 7% topical wash Medimetriks, generic)
- Pacnex® HP (benzoyl peroxide 7% cleansing pads Medimetriks)
- Pacnex® LP (benzoyl peroxide 4.25% cleansing pads Medimetriks)
- Plexion® (sulfacetamide/sulfur 9.8/4.8% cleanser; sulfacetamide/sulfur 9.8/4.8% cleansing pads – Brava)
- Rosula® (sodium sulfacetamide/sulfur 10%/4.5% wash, 10%-5% cleansing cloths Avion)
- Sulfacleanse[®] 8-4 Suspension (sodium sulfacetamide 8%/sulfur 4% Prugen, generic)
- Sumadan® (sodium sulfacetamide/sulfur 9%/4.5% wash Medimetriks)
- Sumadan® XLT (sodium sulfacetamide/sulfur 9%/4.5% wash Medimetriks)
- Sumaxin® (sodium sulfacetamide/sulfur 9%/4% cleansing pads Medimetriks, generic)
- Sumaxin® (sodium sulfacetamide/sulfur 9%/4% wash Medimetriks)
- Sumaxin® CP (sodium sulfacetamide/sulfur 10%/4% Kit Medimetriks)
- Sumaxin® TS (sodium sulfacetamide/sulfur 8%/4% topical suspension – Medimetriks)

REVIEW DATE: 12/20/2023

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the

COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Many topical products are available for the **treatment of acne vulgaris**.^{1,2} Benzoyl peroxide-containing products are generally indicated for the treatment and prevention of mild to moderate acne vulgaris. Sulfacetamide sodium have antimicrobial properties and sulfur have antiseptic properties which aid in the removal of keratin and drying of the skin and are available in a variety of strengths and vehicles. These products (sulfacetamide/sulfur) are additionally used for acne rosacea and seborrheic dermatitis. Acne treatment guidelines do not prefer any of the brand name products over similar generic products.³

The topical products for treatment of acne are available in multiple formulations.^{1,2} Creams and lotions may be best for dry or sensitive skin and gels or foams may be best for more oily skin (although newer aqueous gels may also be suitable for sensitive skin).³

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Note: For the purpose of this policy, a topical cleanser is defined as a cleanser, solution, liquid, wash, foaming cloth, cleansing cloth, or soap.

Topical Acne – Cleanser product(s) is(are) covered as medically necessary when the following step therapy criteria is(are) met. Any other exception is considered not medically necessary.

Step 1: Generic prescription topical acne cleansers containing benzoyl peroxide or sulfacetamide/sulfur

Note: This is not an inclusive list.

- Benzoyl Peroxide 10% Topical Wash
- Sodium Sulfacetamide/Sulfur 10%-4% Cleansing Pads
- Sodium Sulfacetamide 10% and Sulfur 2% Topical Cleanser
- Sulfacetamide Sodium/Sulfur 10%-5% Topical Cleanser
- Sodium Sulfacetamide-Sulfur 9.8%-4.8% Topical Cleanser

Step 2: Branded prescription topical acne cleansers containing benzoyl peroxide or sulfacetamide/sulfur

Note: This is not an inclusive list.

- Avar[™]
- Avar[™] LS
- BP 10-1 Wash
- BP Cleansing Wash
- Pacnex® 7% Topical Wash
- Pacnex® HP Cleansing Pads
- Pacnex[®] LP Cleansing Pads
- Plexion® Cleanser
- Plexion[®] Cleansing Pads
- Rosula[®]
- Sulfacleanse® 8-4 Suspension
- Sumadan®
- Sumadan® XLT
- Sumaxin®
- Sumaxin® CP Kit
- Sumaxin® TS Topical Suspension

CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.

REFERENCES

- 1. Facts and Comparisons® Online. Wolters Kluwer Health, Inc.; 2023. Available at: https://fco.factsandcomparisons.com/lco/action/home. Accessed on December 14, 2023. Search terms: benzoyl peroxide, clindamycin, sulfacetamide/sulfur.
- 2. Clinical Pharmacology © 2023. Available at https://www.clinicalkey.com/pharmacology/. Accessed on December 14, 2023. Search Terms: benzoyl peroxide and sulfur/sulfacetamide.
- 3. Thiboutot DM, Dreno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. *J Am Acad Dermatol*. 2018;78:S1-S23.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual	No criteria changes.	12/14/2022
Revision		
Annual	No criteria changes.	12/20/2023
Revision	-	

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna